Get the Stockscreener App
2.50
0.79%
-0.02
After Hours:
2.52
0.02
+0.80%
Newcelx Ltd stock is traded at $2.50, with a volume of 10,758.
It is down -0.79% in the last 24 hours and down -8.76% over the past month.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
See More
Previous Close:
$2.52
Open:
$2.52
24h Volume:
10,758
Relative Volume:
0.15
Market Cap:
$11.40M
Revenue:
-
Net Income/Loss:
$-2.17M
P/E Ratio:
-0.1441
EPS:
-17.3434
Net Cash Flow:
$-4.82M
1W Performance:
+17.37%
1M Performance:
-8.76%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.50
$2.60
1-Week Range:
$2.0615
$2.65
52-Week Range:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.50 | 11.49M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newcelx Ltd Stock (NCEL) Latest News
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Quantisnow
NCEL SEC FilingsNewcelX Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NewcelX Ltd.Ordinary Shares (NQ: NCEL - The Chronicle-Journal
NewcelX raises $1.35M in private placement at 30% premium By Investing.com - Investing.com Australia
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program - TipRanks
NewcelX Ltd. announced that it expects to receive $1.349994 million in funding - marketscreener.com
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - bitget.com
NewcelX raises $1.35M in private placement at 30% premium - Investing.com
NewcelX Ltd. Secures $2.7 Million in Private Placement to Advance Type 1 Diabetes Program - Quiver Quantitative
NewcelX raises fresh cash for Type 1 diabetes program in premium deal - Stock Titan
NCEL Should I Buy - Intellectia AI
Latest NLSPW NewsNLS Pharmaceutics to Participate in the Be... - Stock Titan
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - Nasdaq
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure - Indian Pharma Post
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
NewcelX and Eledon partner for NCEL-101 programme - Pharmaceutical Business review -
NewcelX (NCEL) Stock Analysis Report | Financials & Insights - Benzinga Japan
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
NewcelX Forms Eledon Alliance to Accelerate NCEL-101 Diabetes Program - TipRanks
NewcelX partners with Eledon on type 1 diabetes therapy - Investing.com
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PR Newswire
NLSPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NCEL | NewcelX Ltd. Ordinary Shares Institutional Ownership - Quiver Quantitative
NCEL | NewcelX Ltd. Ordinary Shares Stock Data, Price & News - Quiver Quantitative
NewcelX Cites Peer-Reviewed Mazindol Data as It Advances CVR-Linked Asset Talks - TipRanks
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - Finviz
NewcelX Updates Corporate Presentation as It Sharpens Focus on Type 1 Diabetes Cell Therapies - TipRanks
NewcelX Announce Positive Results from International Collaborati - GuruFocus
NewcelX Reports Positive International Study Results on Biomaterial-Based Islet Delivery for Type 1 Diabetes - TipRanks
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - marketscreener.com
Newcelx Ltd. Announces Positive Results from International Collaborative Study - marketscreener.com
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX adds Swiss diabetes leader to advisory board to steer IsletRx program - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - marketscreener.com
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Barchart.com
Should I buy NewcelX Ltd. (NCEL) - Zacks Investment Research
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Newcelx Ltd. Share Price (NCEL.US) - London South East
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NCEL|NewcelX Ord Shs|Price:2.255|Chg%:-0.08 - TradingKey
Newcelx Ltd Stock (NCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):